These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 24380881

  • 1. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
    Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, Pronzato MA, Marinari UM, Moretta L, Traverso N, Nitti M.
    Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
    [Abstract] [Full Text] [Related]

  • 2. Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib.
    Furfaro AL, Piras S, Domenicotti C, Fenoglio D, De Luigi A, Salmona M, Moretta L, Marinari UM, Pronzato MA, Traverso N, Nitti M.
    PLoS One; 2016 Apr; 11(3):e0152465. PubMed ID: 27023064
    [Abstract] [Full Text] [Related]

  • 3. Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
    Luo P, Lin M, Lin M, Zhu D, Wang Z, Shen J, Yang B, He Q.
    Pharmazie; 2010 Mar; 65(3):213-8. PubMed ID: 20383943
    [Abstract] [Full Text] [Related]

  • 4. Heme oxygenase-1 nuclear translocation regulates bortezomibinduced cytotoxicity and mediates genomic instability in myeloma cells.
    Tibullo D, Barbagallo I, Giallongo C, Vanella L, Conticello C, Romano A, Saccone S, Godos J, Di Raimondo F, Li Volti G.
    Oncotarget; 2016 May 17; 7(20):28868-80. PubMed ID: 26930712
    [Abstract] [Full Text] [Related]

  • 5. Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
    Tsapakidis K, Vlachostergios PJ, Voutsadakis IA, Befani CD, Patrikidou A, Hatzidaki E, Daliani DD, Moutzouris G, Liakos P, Papandreou CN.
    Int J Urol; 2012 Jun 17; 19(6):565-74. PubMed ID: 22324515
    [Abstract] [Full Text] [Related]

  • 6. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
    Veas-Perez de Tudela M, Delgado-Esteban M, Cuende J, Bolaños JP, Almeida A.
    J Neurochem; 2010 May 17; 113(4):819-25. PubMed ID: 20180881
    [Abstract] [Full Text] [Related]

  • 7. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1.
    Furfaro AL, Macay JR, Marengo B, Nitti M, Parodi A, Fenoglio D, Marinari UM, Pronzato MA, Domenicotti C, Traverso N.
    Free Radic Biol Med; 2012 Jan 15; 52(2):488-96. PubMed ID: 22142473
    [Abstract] [Full Text] [Related]

  • 8. Bortezomib as a therapeutic candidate for neuroblastoma.
    Armstrong MB, Schumacher KR, Mody R, Yanik GA, Opipari AW, Castle VP.
    J Exp Ther Oncol; 2008 Jan 15; 7(2):135-45. PubMed ID: 18771087
    [Abstract] [Full Text] [Related]

  • 9. Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells.
    Tibullo D, Giallongo C, Puglisi F, Tomassoni D, Camiolo G, Cristaldi M, Brundo MV, Anfuso CD, Lupo G, Stampone T, Li Volti G, Amenta F, Avola R, Bramanti V.
    Mol Neurobiol; 2018 Apr 15; 55(4):3344-3350. PubMed ID: 28497200
    [Abstract] [Full Text] [Related]

  • 10. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma.
    Liontas A, Yeger H.
    Anticancer Res; 2004 Apr 15; 24(2B):987-98. PubMed ID: 15161054
    [Abstract] [Full Text] [Related]

  • 11. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
    Luo P, Lin M, Li L, Yang B, He Q.
    PLoS One; 2011 Apr 15; 6(11):e27298. PubMed ID: 22087283
    [Abstract] [Full Text] [Related]

  • 12. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, Brignole C, Di Paolo D, Piaggio F, Perri P, Cilli M, Pastorino F, Ponzoni M.
    J Control Release; 2014 Oct 28; 192():157-66. PubMed ID: 25041999
    [Abstract] [Full Text] [Related]

  • 13. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF.
    Redox Biol; 2016 Aug 28; 8():175-85. PubMed ID: 26795735
    [Abstract] [Full Text] [Related]

  • 14. Characterization of bortezomib-adapted I-45 mesothelioma cells.
    Zhang L, Littlejohn JE, Cui Y, Cao X, Peddaboina C, Smythe WR.
    Mol Cancer; 2010 May 18; 9():110. PubMed ID: 20482802
    [Abstract] [Full Text] [Related]

  • 15. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, Cinatl J, Doerr HW, Cinatl J.
    Int J Oncol; 2006 Feb 18; 28(2):439-46. PubMed ID: 16391799
    [Abstract] [Full Text] [Related]

  • 16. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Du BY, Song W, Bai L, Shen Y, Miao SY, Wang LF.
    Chemotherapy; 2012 Feb 18; 58(1):44-51. PubMed ID: 22327308
    [Abstract] [Full Text] [Related]

  • 17. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.
    Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A.
    Mol Cancer; 2008 Jun 05; 7():50. PubMed ID: 18534018
    [Abstract] [Full Text] [Related]

  • 18. Expression of heme oxygenase-1 in response to proteasomal inhibition.
    Yerlikaya A.
    Protein Pept Lett; 2012 Dec 05; 19(12):1330-3. PubMed ID: 22670665
    [Abstract] [Full Text] [Related]

  • 19. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N.
    J Clin Endocrinol Metab; 2006 Oct 05; 91(10):4013-21. PubMed ID: 16849420
    [Abstract] [Full Text] [Related]

  • 20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.